文章：

通过调节肠道微生物组优化癌症治疗

Optimizing Cancer Treatment Through Gut Microbiome Modulation

原文发布日期：7 April 2025

DOI: 10.3390/cancers17071252

类型: Article

开放获取: 是

英文摘要：

The gut microbiome plays a pivotal role in modulating cancer therapies, including immunotherapy and chemotherapy. Emerging evidence demonstrates its influence on treatment efficacy, immune response, and resistance mechanisms. Specific microbial taxa enhance immune checkpoint inhibitor efficacy, while dysbiosis can contribute to adverse outcomes. Chemotherapy effectiveness is also influenced by microbiome composition, with engineered probiotics and prebiotics offering promising strategies to enhance drug delivery and reduce toxicity. Moreover, microbial metabolites, such as short-chain fatty acids, and engineered microbial systems have shown potential to improve therapeutic responses. These findings underscore the importance of personalized microbiome-based approaches in optimizing cancer treatments.

摘要翻译： 

肠道微生物组在调节癌症治疗（包括免疫疗法和化疗）中发挥着关键作用。最新证据表明，微生物组对治疗效果、免疫应答及耐药机制均具有重要影响。特定微生物类群可增强免疫检查点抑制剂的疗效，而菌群失调则可能导致不良预后。化疗效果同样受微生物组构成的影响，工程化益生菌和益生元为增强药物递送、降低毒性提供了前景广阔的策略。此外，微生物代谢产物（如短链脂肪酸）及工程化微生物系统已显示出改善治疗反应的潜力。这些发现强调了基于个体化微生物组策略在优化癌症治疗中的重要性。

原文链接：

Optimizing Cancer Treatment Through Gut Microbiome Modulation